Chrissy Buteas, President and CEO of the HealthCare Institute of New Jersey (HINJ), has responded to an editorial published on October 27. The editorial allegedly misrepresented the biopharmaceutical, medical technology, and diagnostics sector in New Jersey. Buteas emphasized the industry's role in increasing life expectancy by more than 20 years and its contributions to patient care.
Buteas highlighted the commitment of New Jersey's Congressional Delegation to advancing healthcare solutions. "This is a Delegation that is committed to advancing cures, treatments and technologies that save lives in New Jersey and around the world," she stated. She acknowledged differences in policy opinions but appreciated their balanced approach.
The response also recognized state policymakers, patient advocates, labor leaders, academics, healthcare providers, and business communities for their roles in maintaining New Jersey's leadership in health innovation. "These collective partnerships... are what work together to preserve New Jersey’s global leadership in advancing human health," Buteas noted.
Buteas credited both Democratic and Republican leaders for their thoughtful approaches to complex healthcare decisions. She pointed out that these efforts have contributed significantly to advancements such as curing hepatitis C, developing vaccines against cervical cancer, COVID-19 treatments and vaccines, among others.
She concluded by acknowledging that while there may be disagreements with elected officials on policy matters, they remain dedicated partners in combating diseases globally.
